PERFORM Publications

Keyword search (4,164 papers available)

Title		Authors	PubMed ID
1	The age of obesity onset affects changes in subcutaneous adipose tissue macrophages and T cells after weight loss	Murphy J; Morais JA; Tsoukas MA; Cooke AB; Daskalopoulou SS; Santosa S;	40831565 SOH
2	Age of obesity onset affects subcutaneous adipose tissue cellularity differently in the abdominal and femoral region	Murphy J; Dera A; Morais JA; Tsoukas MA; Khor N; Sazonova T; Almeida LG; Cooke AB; Daskalopoulou SS; Tam BT; Santosa S;	39045668 SOH
3	Methodological considerations for the measurement of arterial stiffness using applanation tonometry	Cooke AB; Kuate Defo A; Dasgupta K; Papaioannou TG; Lee J; Morin SN; Murphy J; Santosa S; Daskalopoulou SS;	33031179 PERFORM
4	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.	Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Laroc	27118291 HKAP
5	Neighbourhood walkability and home neighbourhood-based physical activity: an observational study of adults with type 2 diabetes.	Hajna S, Kestens Y, Daskalopoulou SS, Joseph L, Thierry B, Sherman M, Trudeau L, Rabasa-Lhoret R, Meissner L, Bacon SL, Gauvin L, Ross NA, Dasgupta K, Diabetes, GPS, and Walkablilty Study Group	27613233 HKAP
6	Sex Differences in Clinical Outcomes After Premature Acute Coronary Syndrome.	Pelletier R, Choi J, Winters N, Eisenberg MJ, Bacon SL, Cox J, Daskalopoulou SS, Lavoie KL, Karp I, Shimony A, So D, Thanassoulis G, Pilote L, GENESIS-PRAXY Investigators	27683172 HKAP
7	Physician step prescription and monitoring to improve ARTERial health (SMARTER): A randomized controlled trial in patients with type 2 diabetes and hypertension.	Dasgupta K, Rosenberg E, Joseph L, Cooke AB, Trudeau L, Bacon SL, Chan D, Sherman M, Rabasa-Lhoret R, Daskalopoulou SS, SMARTER Trial Group	28074635 HKAP
8	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults.	Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, Nerenberg K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tran KC, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GVR, Gryn SE, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Sivapalan P, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell	28449828 HKAP
9	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update.	Tobe SW, Stone JA, Anderson T, Bacon S, Cheng AYY, Daskalopoulou SS, Ezekowitz JA, Gregoire JC, Gubitz G, Jain R, Keshavjee K, Lindsay P, L'Abbe M, Lau DCW, Leiter LA, O'Meara E, Pearson GJ, Rabi DM, Sherifali D, Selby P, Tu JV, Wharton S, Walker KM, Hua-Stewart D, Liu PP	30301743 HKAP

Title:	Physician step prescription and monitoring to improve ARTERial health (SMARTER): A randomized controlled trial in patients with type 2 diabetes and hypertension.
Authors:	Dasgupta K, Rosenberg E, Joseph L, Cooke AB, Trudeau L, Bacon SL, Chan D, Sherman M, Rabasa-Lhoret R, Daskalopoulou SS, SMARTER Trial Group
Link:	https://www.ncbi.nlm.nih.gov/pubmed/28074635?dopt=Abstract
Publication:
Keywords:
PMID:	28074635	Category:	Diabetes Obes Metab	Date Added:	2019-05-31
Dept Affiliation:	HKAP 1 Division of Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montréal, Québec, Canada. 2 Division of Endocrinology, McGill University, Montreal, Québec, Canada. 3 Division of Internal Medicine, Department of Medicine, McGill University, Montreal, Québec, Canada. 4 Department of Family Medicine, St. Mary's Hospital, McGill University, Montreal, Québec, Canada. 5 Divisions of Experimental Medicine and Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montréal, Québec, Canada. 6 Cardiovascular Prevention Centre, Jewish General Hospital, McGill University, Montreal, Québec, Canada. 7 Division of Exercise Science, Concordia University, Montreal, Québec, Canada. 8 Institut de Recherches Cliniques de Montréal, Université de Montréal, Montreal, Québec, Canada.

Description:

Physician step prescription and monitoring to improve ARTERial health (SMARTER): A randomized controlled trial in patients with type 2 diabetes and hypertension.

Diabetes Obes Metab. 2017 05;19(5):695-704

Authors: Dasgupta K, Rosenberg E, Joseph L, Cooke AB, Trudeau L, Bacon SL, Chan D, Sherman M, Rabasa-Lhoret R, Daskalopoulou SS, SMARTER Trial Group

Abstract

AIMS: There are few proven strategies to enhance physical activity and cardiometabolic profiles in patients with type 2 diabetes and hypertension. We examined the effects of physician-delivered step count prescriptions and monitoring.

METHODS: Participants randomized to the active arm were provided with pedometers and they recorded step counts. Over a 1-year period, their physicians reviewed their records and provided a written step count prescription at each clinic visit. The overall goal was a 3000 steps/day increase over 1 year (individualized rate of increase). Control arm participants were advised to engage in physical activity 30 to 60 min/day. We evaluated effects on step counts, carotid femoral pulse wave velocity (cfPWV, primary) and other cardiometabolic indicators including haemoglobin A1c in diabetes (henceforth abbreviated as A1c) and Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) in participants not receiving insulin therapy.

RESULTS: A total of 79% completed final evaluations (275/347; mean age, 60 years; SD, 11). Over 66% of participants had type 2 diabetes and over 90% had hypertension. There was a net 20% increase in steps/day in active vs control arm participants (1190; 95% CI, 550-1840). Changes in cfPWV were inconclusive; active vs control arm participants with type 2 diabetes experienced a decrease in A1c (-0.38%; 95% CI, -0.69 to -0.06). HOMA-IR also declined in the active arm vs the control arm (ie, assessed in all participants not treated with insulin; -0.96; 95% CI, -1.72 to -0.21).

CONCLUSIONS: A simple physician-delivered step count prescription strategy incorporated into routine clinical practice led to a net 20% increase in step counts; however, this was below the 3000 steps/day targeted increment. While conclusive effects on cfPWV were not observed, there were improvements in both A1c and insulin sensitivity. Future studies will evaluate an amplified intervention to increase impact.

PMID: 28074635 [PubMed - indexed for MEDLINE]

BookR: School of Health Core Facilities Booking

"Daskalopoulou SS" Authored Publications:

Search Publications

No results